AC
CMLFU

Aaron Cowen’s CM Life Sciences, Inc. Unit CMLFU Stock Holding History

Aaron Cowen’s Portfolio CMLFU Stock Details CMLFU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-254,713
Closed -$2.67M – 136
2020
Q3 		$2.67M Buy
+254,713
New +$2.68M 0.05% 77

Other funds holding CMLFU

SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BCP
Berylson Capital Partners Boston, Massachusetts $41.2M AUM 0.19% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aaron Cowen's CMLFU Position: Q4 2020 in Review

Aaron Cowen sold out of CM Life Sciences, Inc. Unit (CMLFU) in Q4 2020, closing a stake of 254,713 shares — an estimated $2.67M sold.

Aaron Cowen first reported a position in CMLFU in Q3 2020 and held it in 1 quarter. The position peaked at $2.67M in Q3 2020. 42 funds tracked by Wall St. Rank hold CMLFU as of Q4 2020.

  • Aaron Cowen reported no remaining CM Life Sciences, Inc. Unit position as of Q4 2020 after selling out during the quarter.
  • Aaron Cowen sold 254,713 CM Life Sciences, Inc. Unit shares in Q4 2020, an estimated $2.67M.
  • Aaron Cowen first reported a position in CM Life Sciences, Inc. Unit in Q3 2020 and held it in 1 quarter.
  • Aaron Cowen's CM Life Sciences, Inc. Unit position peaked at $2.67M in Q3 2020.
  • 42 funds tracked by Wall St. Rank held CM Life Sciences, Inc. Unit as of Q4 2020.

Based on Suvretta Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.